PT-141 (Bremelanotide): What Men Should Know About Off-Label Use

If you've struggled with erectile dysfunction or low libido and traditional medications like Viagra or Cialis haven't worked, you may have heard about PT-141 — a peptide that takes an entirely different approach to sexual health. Unlike conventional ED drugs that target blood flow, PT-141 works through the brain, and that distinction is generating significant interest among men and their physicians.

Here's what the current evidence says — and what you should consider before exploring this option.

What Is PT-141?

PT-141, known generically as bremelanotide and sold under the brand name Vyleesi, is a synthetic peptide derived from Melanotan II, a compound originally studied for its tanning effects. Researchers discovered that the peptide had a pronounced effect on sexual arousal, which led to its development as a standalone therapy for sexual dysfunction.

In 2019, the FDA approved bremelanotide for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. That approval, however, does not extend to men. Any use of PT-141 in men is considered off-label — meaning a physician may prescribe it based on clinical judgment and emerging evidence, but it has not been formally evaluated and approved by the FDA for male sexual dysfunction.

How It Works: A Brain-Based Mechanism

Most ED medications are PDE5 inhibitors. They work by relaxing blood vessels in the penis, improving blood flow to help achieve and maintain an erection. They require sexual stimulation to be effective and do nothing to address desire itself.

PT-141 works through an entirely different pathway. It is a melanocortin receptor agonist, meaning it activates melanocortin receptors (specifically MC4R) in the central nervous system — the same neural pathways naturally involved in regulating sexual arousal and motivation. Rather than acting on the vascular system, it targets the brain's arousal centers to enhance desire at its source.

This distinction matters clinically. An estimated 30–40% of men with ED see little to no improvement from PDE5 inhibitors alone. For men whose dysfunction is rooted in low desire, psychological factors, or a combination of vascular and neurological issues, a brain-based approach may address what blood-flow drugs cannot.

What Does the Research Show?

The evidence for PT-141 in men is still developing, but early findings are encouraging.

Clinical trials using an intranasal formulation found that PT-141 produced statistically significant erectile responses compared to placebo at higher doses, with the first erection typically occurring roughly 30 minutes after administration. In one study, approximately 34% of men in the bremelanotide group reported the ability to achieve and maintain erections sufficient for intercourse, compared to just 9% receiving placebo.

Research into combination therapy has also shown promise. A study examining bremelanotide alongside low-dose sildenafil found that the combination produced a significantly greater erectile response than sildenafil alone — suggesting the two mechanisms may work synergistically. This is particularly relevant for PDE5 inhibitor non-responders who may benefit from a dual approach.

A 2024 observational study from a sexual medicine clinic examined 21 men with various sexual dysfunctions — including low libido, ED, and difficulty with orgasm — who used subcutaneous bremelanotide on an as-needed basis. The results added to the growing body of real-world evidence supporting its potential effectiveness.

A Phase IIB trial examining bremelanotide in men with diabetes-related ED also reported significant improvements in International Index of Erectile Function (IIEF) scores, which is noteworthy given that diabetic ED is notoriously difficult to treat with conventional therapies.

How Is It Administered?

The FDA-approved formulation is a 1.75 mg subcutaneous injection, self-administered via an autoinjector pen in the abdomen or thigh. For off-label male use, physicians typically follow the same dose and method. The injection is taken approximately 45 minutes before anticipated sexual activity, with peak effects generally occurring one to two hours after administration.

Some compounding pharmacies also offer intranasal formulations, which appeal to patients who prefer to avoid injections. However, robust data on compounded nasal formulations is limited, and quality can vary between pharmacies.

Dosing guidelines generally recommend no more than one dose per 24 hours and no more than eight doses per month.

Side Effects and Safety Considerations

PT-141 is not without risks. The most commonly reported side effects include:

• Nausea — the most frequent complaint, occurring in roughly 40% of patients. It is usually mild and transient, lasting about two hours, but can be severe in some cases.
• Flushing — brief and typically mild.
• Blood pressure changes — bremelanotide causes small, transient increases in blood pressure (approximately 6 mmHg systolic and 3 mmHg diastolic), peaking within four hours and returning to baseline by eight to ten hours.
• Skin darkening — because PT-141 is derived from Melanotan II, some users may notice mild hyperpigmentation, particularly of the gums, face, or skin. These changes may be permanent.

Due to its effects on blood pressure, PT-141 is contraindicated for individuals with uncontrolled hypertension or cardiovascular disease. A cardiovascular assessment before starting therapy is strongly recommended.

Long-term safety data remains limited, as most research has evaluated PT-141 for short-term, on-demand use.

The Path Toward Formal Approval

Palatin Technologies, the developer of bremelanotide, has been conducting Phase II trials evaluating a combination bremelanotide-and-PDE5 inhibitor therapy specifically for male ED. If results are positive, the company plans to advance to larger Phase III trials with the goal of achieving the first FDA approval for a new class of ED medication in over two decades.

The Bottom Line

PT-141 represents a genuinely novel approach to male sexual dysfunction — one that addresses desire and arousal through the brain rather than blood vessels alone. For men who haven't responded to traditional ED medications, it may offer a meaningful alternative or complement.

That said, its use in men remains off-label and investigational. The evidence is promising but not yet definitive, and important questions about long-term safety and optimal dosing are still being studied.

If you're considering PT-141, the most important step is an honest conversation with a qualified healthcare provider who can evaluate your specific situation, review your cardiovascular health, and help you weigh the potential benefits against the known risks.

This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any new treatment.